This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Timmermans, C. Articles by Wellens, H. J. J. Search for Related Content PubMed PubMed Citation Articles by Timmermans, C. Articles by Wellens, H. J. J. Related Collections Electrophysiology Cardiovascular Pharmacology Arrhythmias, clinical electrophysiology, drugs

(Circulation. 1999;99:1837-1842.)
© 1999 American Heart Association, Inc.

Clinical Investigation and Reports

Effect of Butorphanol Tartrate on Shock-Related Discomfort During Internal Atrial Defibrillation

Carl Timmermans, MD, ; Luz-Maria Rodriguez, MD, ; Gregory M. Ayers, MD, ; Hendrik Lambert, PhD, ; Joep L. R. M. Smeets, MD, ; Johan W. S. Vlaeyen, PhD, ; Adelin Albert, PhD, ; Hein J. J. Wellens, MD,

From the Department of Cardiology (C.T., L.M.R., J.L.R.M.S, H.J.J.W.) and Pain Management and Research Center (J.W.S.V.), Academic Hospital Maastricht (The Netherlands); the Department of Biostatistics (A.A.), University of Liège (Belgium); and InControl Inc (G.M.A., H.L.), Redmond, Wash.

Correspondence to Carl Timmermans, Department of Cardiology, Academic Hospital Maastricht, CARIM (Cardiovascular Research Institute Maastricht), P. Debeyelaan 25, PO Box 5800, Maastricht, The Netherlands. E-mail C.Timmermans{at}cardio.azm.nl

Background—In patients with atrial fibrillation, intracardiac atrial defibrillation causes discomfort. An easily applicable, short-acting analgesic and anxiolytic drug would increase acceptability of this new treatment mode.

Methods and Results—In a double-blind, placebo-controlled manner, the effect of intranasal butorphanol, an opioid, was evaluated in 47 patients with the use of a step-up internal atrial defibrillation protocol (stage I). On request, additional butorphanol was administered and the step-up protocol continued (stage II). Thereafter, if necessary, patients were intravenously sedated (stage III). After each shock, the McGill Pain Questionnaire was used to obtain a sensory (S), affective (A), evaluative (E), and total (T) pain rating index (PRI) and a visual analogue scale analyzing pain (VAS-P) and fear (VAS-F). For every patient, the slope of each pain or fear parameter against the shock number was calculated and individual slopes were averaged for the placebo and butorphanol group. All patients were cardioverted at a mean threshold of 4.4±3.3 J. Comparing both patient groups for stage II, the mean slopes for PRI-T (P=0.0099), PRI-S (P=0.019), and PRI-E (P=0.015) became significantly lower in the butorphanol group than in the placebo group. Comparing patients who received the same shock intensity ending stage I and going to stage II, in those patients randomized to placebo the mean VAS-P (P=0.023), PRI-T (P=0.029), PRI-S (P=0.030), and PRI-E (P=0.023) became significantly lower after butorphanol administration.

Conclusions—During a step-up internal atrial defibrillation protocol, intranasal butorphanol decreased or stabilized the value of several pain variables and did not affect fear. Of the 3 qualitative components of pain, only the affective component was not influenced by butorphanol. The PRI evaluated pain more accurately than the VAS.

Key Words: atrium • fibrillation • defibrillation

This article has been cited by other articles:

				J.C. Geller, S. Reek, C. Timmermans, T. Kayser, H.-F. Tse, C. Wolpert, W. Jung, A.J. Camm, C.-P. Lau, H. J.J. Wellens, et al. Treatment of atrial fibrillation with an implantable atrial defibrillator -- long term results Eur. Heart J., December 1, 2003; 24(23): 2083 - 2089. [Abstract] [Full Text] [PDF]

				E. G. Daoud, C. Timmermans, C. Fellows, R. Hoyt, R. Lemery, K. Dawson, and G. M. Ayers Initial Clinical Experience With Ambulatory Use of an Implantable Atrial Defibrillator for Conversion of Atrial Fibrillation Circulation, September 19, 2000; 102(12): 1407 - 1413. [Abstract] [Full Text] [PDF]

				C. Timmermans, A. Nabar, L.-M. Rodriguez, G. Ayers, and H. J. J. Wellens Use of Sedation During Cardioversion With the Implantable Atrial Defibrillator Circulation, October 5, 1999; 100(14): 1499 - 1501. [Abstract] [Full Text] [PDF]